Effects of RXR Agonists on Cell Proliferation/ Apoptosis and ACTH Secretion/Pomc Expression

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Saito Hakoda, Akiko ^a   Uruno, Akira ^a   Yokoyama, Atsushi ^a   Shimizu, Kyoko ^a   Parvin, Rehana ^a   Kudo, Masataka ^a   Saito Ito, Takako ^a   Sato, Ikuko ^a   Kogure, Naotaka ^a   Suzuki, Dai ^a   Yoshikawa, Takeo ^a   Fujiwara, Ikuma ^a   Kagechika, Hiroyuki ^b   Iwasaki, Yasumasa ^c   Kure, Shigeo ^a   Ito, Sadayoshi ^a   Sugawara, Akira ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOTROPIN; HX 630; MESSENGER RNA; NEUROGENIC DIFFERENTIATION FACTOR; NUCLEAR RECEPTOR NUR77; NUCLEAR RECEPTOR RELATED FACTOR 1; PA 024; PROOPIOMELANOCORTIN; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; UNCLASSIFIED DRUG; 2 NAPHTHYLAMINE; BENZAZEPINE DERIVATIVE; BENZOIC ACID DERIVATIVE; PA024 COMPOUND; PYRIMIDINE DERIVATIVE; RETINOID X RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORTICOTROPH TUMOR; CORTICOTROPIN RELEASE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HYPOPHYSIS TUMOR; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROMOTER REGION; PROOPIOMELANOCORTIN GENE; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHLOROCEBUS AETHIOPS; CUSHING SYNDROME; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PRECLINICAL STUDY; SECRETION (PROCESS); TUMOR CELL LINE;

2-NAPHTHYLAMINE; ADRENOCORTICOTROPIC HORMONE; ANIMALS; APOPTOSIS; BENZAZEPINES; BENZOATES; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CUSHING SYNDROME; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRO-OPIOMELANOCORTIN; PROMOTER REGIONS, GENETIC; PYRIMIDINES; RETINOID X RECEPTORS;

EID: 84958213247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141960     Document Type: Article

References (50)

1. Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7: 279-289. doi: 10.1038/nrendo.2011.12 PMID: 21301487.
2. Alexandraki KI, Grossman AB (2008) Pituitary-targeted medical therapy of Cushing's disease. Expert Opin Investig Drugs 17: 669-677. doi: 10.1517/13543784.17.5.669 PMID: 18447593.
3. Bushue N, Wan YJ (2010) Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 62: 1285- 1298. doi: 10.1016/j.addr.2010.07.003 PMID: 20654663.
4. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, et al. (2001) Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108: 1123-1131. PMID: 11602619.
5. Giacomini D, Paez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, et al. (2006) Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147: 247-256. PMID: 16195406.
6. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, et al. (2006) Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 147: 4438-4444. PMID: 16740975.
7. Labeur M, Paez-Pereda M, Arzt E, Stalla GK (2009) Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas. Rev Endocr Metab Disord 10: 103-109. doi: 10.1007/s11154- 008-9080-6 PMID: 18604646.
8. Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, et al. (2012) Potential role for retinoic acid in patients with Cushing's disease. J Clin Endocrinol Metab 97: 3577-3583. doi: 10.1210/jc.2012-2328 PMID: 22851491.
9. Uruno A, Saito-Hakoda A, Yokoyama A, Kogure N, Matsuda K, Parvin R, et al. (2014) Retinoic acid receptor-α up-regulates proopiomelanocortin gene expression in AtT20 corticotroph cells. Endocr J 61: 1105-1114. PMID: 25132258.
10. Lefebvre P, Benomar Y, Staels B (2010) Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab 21: 676-683. doi: 10.1016/j.tem.2010.06.009 PMID: 20674387.
11. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. (2006) International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 58: 760-772. PMID: 17132853.
12. Tanaka T, De Luca LM (2009) Therapeutic potential of "rexinoids" in cancer prevention and treatment. Cancer Res 69: 4945-4947. doi: 10.1158/0008-5472.CAN-08-4407 PMID: 19509234.
13. Liby KT, Yore MM, Sporn MB (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7: 357-369. PMID: 17446857.
14. Howe LR (2007) Rexinoids and breast cancer prevention. Clin Cancer Res 13: 5983-5987. PMID: 17947457.
15. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H (2007) RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6: 793-810. PMID: 17906642.
16. Qu L, Tang X (2010) Bexarotene: a promising anticancer agent. Cancer Chemother Pharmacol 65: 201-205. doi: 10.1007/s00280-009-1140-4 PMID: 19777233.
17. Umemiya H, Kagechika H, Fukasawa H, Kawachi E, Ebisawa M, Hashimoto Y, et al. (1997) Action mechanism of retinoid-synergistic dibenzodiazepines. Biochem Biophys Res Commun 233: 121-125. PMID: 9144408.
18. Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, Eisenmann G, et al. (1997) Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J Med Chem 40: 4222-4234. PMID: 9435893.
19. Takahashi B, Ohta K, Kawachi E, Fukasawa H, Hashimoto Y, Kagechika H (2002) Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimer actions. J Med Chem 45: 3327-3330. PMID: 12139443.
20. Kagechika H, Shudo K (2005) Synthetic retinoids: recent developments concerning structure and clinical utility. J Med Chem 48: 5875-5883. PMID: 16161990.
21. Sugawara A, Uruno A, Kudo M, Ikeda Y, Sato K, Taniyama Y, et al. (2002) Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J Biol Chem 277: 9676-9683. PMID: 11777901.
22. Umesono K, Murakami KK, Thompson CC, Evans RM (1991) Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65: 1255-1266. PMID: 1648450.
23. Yen PM, Liu Y, Sugawara A, Chin WW (1996) Vitamin D receptors repress basal transcription and exert dominant negative activity on triiodothyronine-mediated transcriptional activity. J Biol Chem 271: 10910-10916. PMID: 8631908.
24. Cwikel BJ, Habener JF (1987) Provasopressin-neurophysin II processing is cell-specific in heterologous cell lines expressing a metallothionein-vasopressin fusion gene. J Biol Chem 262: 14235-14240. PMID: 3654660.
25. Dai A, Yan G, He Q, Jiang Y, Zhang Q, Fang T, et al. (2012) Orphan nuclear receptor Nur77 regulates androgen receptor gene expression in mouse ovary. PLoS One 7: e39950. doi: 10.1371/journal.pone. 0039950 PMID: 22761936.
26. Spyroglou A, Manolopoulou J, Wagner S, Bidlingmaier M, Reincke M, Beuschlein F (2009) Short term regulation of aldosterone secretion after stimulation and suppression experiments in mice. J Mol Endocrinol 42: 407-413. doi: 10.1677/JME-08-0167 PMID: 19221003.
27. Kudo M, Matsuda K, Sugawara K, Iki Y, Kogure N, Saito-Ito T, et al. (2014) ARB affects nicotine-induced gene expression profile in human coronary artery endothelial cells.World J Hypertens 4: 7-14.
28. Sugawara A, Yen PM, Qi Y, Lechan RM, Chin WW (1995) Isoform-specific retinoid-X receptor (RXR) antibodies detect differential expression of RXR proteins in the pituitary gland. Endocrinology 136: 1766-1774. PMID: 7895689.
29. Philips A, Lesage S, Gingras R, Maira MH, Gauthier Y, Hugo P, et al. (1997) Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol 17: 5946-5951. PMID: 9315652.
30. Maira M, Martens C, Philips A, Drouin J (1999) Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol 19: 7549- 7557. PMID: 10523643.
31. Therrien M, Drouin J (1993) Cell-specific helix-loop-helix factor required for pituitary expression of the pro-opiomelanocortin gene. Mol Cell Biol 13: 2342-2353. PMID: 8455616.
32. Poulin G, Turgeon B, Drouin J (1997) NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol 17: 6673-6682. PMID: 9343431.
33. Zhang XK, Lehmann J, Hoffmann B, Dawson MI, Cameron J, Graupner G, et al. (1992) Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 358: 587-591. PMID: 1323763.
34. Pérez E, Bourguet W, Gronemeyer H, de Lera AR (2012) Modulation of RXR function through ligand design. Biochim Biophys Acta 1821: 57-69. doi: 10.1016/j.bbalip.2011.04.003 PMID: 21515403.
35. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, et al. (1997) Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15: 790-795. PMID: 9053506.
36. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. (2001) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137: 581-593. PMID: 11346336.
37. Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, et al. (2008) UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 7: 3780-3788. doi: 10.1158/1535-7163. MCT-08-0753 PMID: 19074853.
38. Tanaka T, Suh KS, Lo AM, De Luca LM (2007) p21WAF1/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)/retinoid X receptor (RXR) heterodimer and RXR/RXR homodimer. J Biol Chem 282: 29987-29997. PMID: 17656367.
39. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M (2002) Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 8: 1234- 1240. PMID: 12006543.
40. Matsumoto S, Hashimoto K, Yamada M, Satoh T, Hirato J, Mori M (2009) Liver X receptor-alpha regulates proopiomelanocortin (POMC) gene transcription in the pituitary. Mol Endocrinol 23: 47-60. doi: 10.1210/me.2007-0533 PMID: 19036902.
41. Hashimoto K, Matsumoto S, Ishida E, Miura A, Horiguchi K, Ozawa A, et al. (2011) Liver X receptoralpha/beta expression ratio is increased in ACTH-secreting pituitary adenomas. Neurosci Lett 494: 34-37. doi: 10.1016/j.neulet.2011.02.048 PMID: 21356276.
42. Heaney AP, Fernando M, Yong WH, Melmed S (2002) Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8: 1281-1287. PMID: 12379847.
43. Heaney AP (2003) Novel pituitary ligands: peroxisome proliferator activating receptor-gamma. Pituitary 6: 153-159. PMID: 14971739.
44. Crowe DL, Chandraratna RA (2004) A retinoid X receptor (RXR)-selective retinoid reveals that RXRalpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6: R546-R555. PMID: 15318936.
45. Jenks BG (2009) Regulation of proopiomelanocortin gene expression: an overview of the signaling cascades, transcription factors, and responsive elements involved. Ann N Y Acad Sci 1163: 17-30. doi: 10.1111/j.1749-6632.2008.03620.x PMID: 19456325.
46. Wilson TE, Fahrner TJ, Johnston M, Milbrantdt J (1991) Identification of the DNA binding site for NGFIB by genetic selection in yeast. Science 252: 1296-1300. PMID: 1925541.
47. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, et al. (2001) A pituitary cellrestricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104: 849-859. PMID: 11290323.
48. Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C (2004) NF-kappaB participates in the corticotropin- releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem 278: 10837-10840.
49. Nishimaki-Mogami T, Tamehiro N, Sato Y, Okuhira K, Sai K, Kagechika H, et al. (2008) The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines. Biochem Pharmacol 76: 1006-1013. doi: 10.1016/j.bcp.2008.08.005 PMID: 18761326.
50. Ishida S, Shigemoto-Mogami Y, Kagechika H, Shudo K, Ozawa S, Sawada J, et al. (2003) Clinically potential subclasses of retinoid synergists revealed by gene expression profiling. Mol Cancer Ther 2: 49-58. PMID: 12533672.